Brian Wayda1, Alexander T Sandhu2, Justin Parizo2, Jeffrey J Teuteberg2, Kiran K Khush2. 1. Division of Cardiology; Stanford Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: bwayda@stanford.edu. 2. Division of Cardiology; Stanford Cardiovascular Institute, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Abstract
BACKGROUND: The advent of direct-acting antiviral therapy for Hepatitis C (HCV) has made using HCV-viremic donors a viable strategy to address the donor shortage in heart transplantation. We employed a large-scale simulation to evaluate the impact and cost-effectiveness of using HCV-viremic donors for heart transplant. METHODS: We simulated detailed histories from time of listing until death for the real-world cohort of all adults listed for heart transplant in the United States from July 2014 to June 2019 (n = 19,346). This population was imputed using historical data and captures "real-world" heterogeneity in geographic and clinical characteristics. We estimated the impact of an intervention in which all candidates accept HCV+ potential donors (n = 472) on transplant volume, waitlist outcomes, and lifetime costs and quality-adjusted life years (QALYs). RESULTS: The intervention produced 232 more transplants, 132 fewer delistings due to deterioration, and 50 fewer waitlist deaths within this 5-year cohort and reduced wait times by 3% to 11% (varying by priority status). The intervention was cost-effective, adding an average of 0.08 QALYs per patient at a cost of $124 million ($81,892 per QALY). DAA therapy and HCV care combined account for 11% this cost, with the remainder due to higher costs of transplant procedures and routine post-transplant care. The impact on transplant volume varied by blood type and region and was correlated with donor-to-candidate ratio (ρ = 0.71). CONCLUSIONS: Transplanting HCV+ donor hearts is likely to be cost-effective and improve waitlist outcomes, particularly in regions and subgroups experiencing high donor scarcity.
BACKGROUND: The advent of direct-acting antiviral therapy for Hepatitis C (HCV) has made using HCV-viremic donors a viable strategy to address the donor shortage in heart transplantation. We employed a large-scale simulation to evaluate the impact and cost-effectiveness of using HCV-viremic donors for heart transplant. METHODS: We simulated detailed histories from time of listing until death for the real-world cohort of all adults listed for heart transplant in the United States from July 2014 to June 2019 (n = 19,346). This population was imputed using historical data and captures "real-world" heterogeneity in geographic and clinical characteristics. We estimated the impact of an intervention in which all candidates accept HCV+ potential donors (n = 472) on transplant volume, waitlist outcomes, and lifetime costs and quality-adjusted life years (QALYs). RESULTS: The intervention produced 232 more transplants, 132 fewer delistings due to deterioration, and 50 fewer waitlist deaths within this 5-year cohort and reduced wait times by 3% to 11% (varying by priority status). The intervention was cost-effective, adding an average of 0.08 QALYs per patient at a cost of $124 million ($81,892 per QALY). DAA therapy and HCV care combined account for 11% this cost, with the remainder due to higher costs of transplant procedures and routine post-transplant care. The impact on transplant volume varied by blood type and region and was correlated with donor-to-candidate ratio (ρ = 0.71). CONCLUSIONS: Transplanting HCV+ donor hearts is likely to be cost-effective and improve waitlist outcomes, particularly in regions and subgroups experiencing high donor scarcity.
Authors: Linda D Sharples; Matthew Dyer; Fay Cafferty; Nikolaos Demiris; Carol Freeman; Nicholas R Banner; Stephen R Large; Steven Tsui; Noreen Caine; Martin Buxton Journal: J Heart Lung Transplant Date: 2006-11 Impact factor: 10.247
Authors: Kathleen L Grady; David Naftel; Lynne Stevenson; Mary Amanda Dew; Gerdi Weidner; Francis D Pagani; James K Kirklin; Susan Myers; Timothy Baldwin; James Young Journal: J Heart Lung Transplant Date: 2013-10-23 Impact factor: 10.247
Authors: James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; J T Baldwin; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: Alexander Göhler; Benjamin P Geisler; Jennifer M Manne; Mikhail Kosiborod; Zefeng Zhang; William S Weintraub; John A Spertus; G Scott Gazelle; Uwe Siebert; David J Cohen Journal: Value Health Date: 2008-07-18 Impact factor: 5.725
Authors: Cathy Logan; Ily Yumul; Javier Cepeda; Victor Pretorius; Eric Adler; Saima Aslam; Natasha K Martin Journal: Am J Transplant Date: 2020-09-15 Impact factor: 8.086